{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"15.8","value":"4.7"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"8.0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"44"}],"units":"Participants"}],"description":"CRh was defined as \\<5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets \\>50,000/μL and ANC \\>500/μL), independence from RBC and platelet transfusions within 7 days of bone marrow evaluation, and peripheral blast ≤1%. Percentage of participants with CRh based on IWG 2003 AML response criteria are reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with AML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\\^2, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.","id":"OG000","title":"AML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727"},{"description":"Participants with AML received IV infusion of decitabine 20 mg/m\\^2, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days) followed by ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, participant discontinued treatment, or was withdrawn from the study.","id":"OG001","title":"AML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727"}],"paramType":"NUMBER","populationDescription":"Efficacy Analysis Set included all participants who received any amount of study treatment.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 3 up to approximately 2.4 years (each cycle= 28 days)","title":"AML: Percentage of Participants With CR With Partial Hematologic Recovery (CRh) Based on IWG 2003 AML Response Criteria","type":"SECONDARY","unitOfMeasure":"percentage of participants"}